source
- Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s nextIntellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and potentially dangerous…Endpoints · 3mo ago↗ source
- Thermo Fisher sells microbiology biz; Ligand to buy XOMAThermo Fisher Scientific sells microbiology business: Astorg, a European private equity firm, will acquire the unit for $1.075 billion. Thermo Fisher’s microbiology business is part of its specialt…Endpoints · 3mo ago↗ source
- Oruka posts Phase 2 win in psoriasis, hoping to compete with SkyriziOruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug…